文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

合成聚（L-谷氨酸）缀合的CpG在黑色素瘤小鼠模型中瘤内注射后，在肿瘤和引流淋巴结中滞留增加，表现出抗肿瘤功效。

Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.

作者信息

Ma Qing, Zhou Dapeng, DeLyria Elizabeth S, Wen Xiaoxia, Lu Wei, Thapa Prakash, Liu Chengwen, Li Dan, Bassett Roland L, Overwijk Willem W, Hwu Patrick, Li Chun

机构信息

Departments of *Stem Cell Transplantation and Cellular Therapy †Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China ‡Melanoma Medical Oncology §Cancer Systems Imaging ∥Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

J Immunother. 2017 Jan;40(1):11-20. doi: 10.1097/CJI.0000000000000145.

DOI:10.1097/CJI.0000000000000145
PMID:27681378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5138115/
Abstract

There is an urgent need for new clinically applicable drug-delivery methods to enhance accumulation of immune-activating drugs in tumors. We synthesized a poly(L-glutamic acid)-CpG ODN2216 conjugate (PG-CpG) and injected it intratumorally into C57BL/6 mice bearing subcutaneous B16-ovalbumin melanoma. PG-CpG elicited the same potent antitumoral activity as CpG with respect to reducing tumor growth and triggering antigen-specific CD8 T-cell responses in this well-established solid tumor model. Moreover, PG-CpG was retained significantly longer in both tumor and draining lymph nodes than was free CpG after intratumoral injection. Specifically, 48 hours after injection, 26.5%±16.9% of the injected PG-CpG dose versus 4.72%±2.61% of free CpG remained at the tumor, and 1.53%±1.22% of the injected PG-CpG versus 0.37%±0.33% of free CpG was retained in the draining inguinal lymph nodes. These findings indicate that PG is an effective synthetic polymeric carrier for delivery of immunostimulatory agents to tumors and lymph nodes.

摘要

迫切需要新的临床适用药物递送方法，以增强免疫激活药物在肿瘤中的蓄积。我们合成了聚（L-谷氨酸）-CpG ODN2216缀合物（PG-CpG），并将其瘤内注射到携带皮下B16-卵清蛋白黑色素瘤的C57BL/6小鼠体内。在这个成熟的实体瘤模型中，就减少肿瘤生长和触发抗原特异性CD8 T细胞反应而言，PG-CpG引发了与CpG相同的强效抗肿瘤活性。此外，瘤内注射后，PG-CpG在肿瘤和引流淋巴结中的保留时间明显长于游离CpG。具体而言，注射后48小时，注射剂量的26.5%±16.9%的PG-CpG留在肿瘤中，而游离CpG为4.72%±2.61%；1.53%±1.22%的注射PG-CpG保留在引流的腹股沟淋巴结中，而游离CpG为0.37%±0.33%。这些发现表明，PG是一种有效的合成聚合物载体，可用于将免疫刺激剂递送至肿瘤和淋巴结。

相似文献

[1]
Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.

J Immunother. 2017-1

[2]
Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.

Immunol Cell Biol. 2008

[3]
Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.

J Immunother. 2006

[4]
Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.

J Immunother. 2006

[5]
Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.

J Immunol. 2017-2-15

[6]
Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.

J Immunother. 2010-4

[7]
Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models.

Cancer Immunol Immunother. 2016-5

[8]
Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.

Int Immunopharmacol. 2013-12

[9]
Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.

Bioconjug Chem. 2017-7-19

[10]
Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses.

J Control Release. 2014-12-23

引用本文的文献

[1]
Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment.

Beilstein J Nanotechnol. 2025-3-27

[2]
Unlocking the tumor-immune microenvironment in osteosarcoma: insights into the immune landscape and mechanisms.

Front Immunol. 2024

[3]
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy.

J Nanobiotechnology. 2023-9-21

[4]
Novel Immunotherapies for Osteosarcoma.

Front Oncol. 2022-4-1

[5]
CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials.

Pharmaceutics. 2021-12-28

[6]
Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists.

Cancers (Basel). 2020-12-18

[7]
An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.

Cancer Med. 2020-12

[8]
Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition.

Nanomedicine. 2020-4

[9]
Biomaterials for vaccine-based cancer immunotherapy.

J Control Release. 2018-10-9

本文引用的文献

[1]
Structure-based programming of lymph-node targeting in molecular vaccines.

Nature. 2014-2-16

[2]
Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy.

PLoS One. 2013-5-15

[3]
Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice.

Clin Cancer Res. 2012-8-17

[4]
Antitumor activity mediated by CpG: the route of administration is critical.

J Immunother. 2011-4

[5]
Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813.

Biomaterials. 2010-9

[6]
Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity.

J Immunol. 2008-9-1

[7]
Polymer-drug conjugates: recent development in clinical oncology.

Adv Drug Deliv Rev. 2008-5-22

[8]
Development of a macromolecular dual-modality MR-optical imaging for sentinel lymph node mapping.

Invest Radiol. 2007-8

[9]
A novel method for imaging in vivo degradation of poly(L-glutamic acid), a biodegradable drug carrier.

Pharm Res. 2007-6

[10]
TLR pathways and IFN-regulatory factors: to each its own.

Eur J Immunol. 2007-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索